Organ-on-a-Chip: Global Markets
The global organ-on-a-chip market should reach $183.4 million by 2026 from $32.0 million in 2021 at a compound annual growth rate (CAGR) of 41.8% for the forecast period of 2021 to 2026.
- 55 data tables and 29 additional tables
- An up-to-date review and analysis of the global markets for organ-on-a-chip within the biotech industry
- Analyses of the global market trends, with data from 2019 to 2021, and projections of compound annual growth rates (CAGRs) through 2026
- Information on multi-channel 3-D microfluidic cell culture chip, and discussion of their ability to imitate human microenvironment in vitro
- Evaluation and forecast the global organ-on-a-chip market size, and corresponding market share analysis by technology offering, organ type, application, end-user vertical and region
- Discussion on how organ-on-a-chip is emerging as a priority testing alternative which is replacing animals in life science research, toxicology testing and drug development studies
- Review of potential applications in pharmaceutical and life science research sectors, including preclinical drugs testing, drug screening, personalized medicine, phenotypic screening, lead optimization and disease modelling
- Insights into the recent industry structure including the government programs and policies in support of organ-on-a-chip and coverage of revised laws involving animal testing
- Review of patent grants for innovations in organ-on-a-chip technology across each major category
- Descriptive company profiles of the leading global players, including 4Dcell, BiomimX, Emulate Inc., Kirkstall Ltd., Nortis and TissUse GmbH
The scope of this report covers various types of products available in the organ-on-a-chip market and potential application sectors in various industries. The organ-on-a-chip market is broken down into various segments. Revenue forecasts from 2019 to 2026 are given for each type, application, offering and end user. Revenue generated from the installation and maintenance of instruments has been excluded from the report. The application segment is characterized by various types, including drug discovery and development, toxicological research, and physiological model development, and by end-use industry, including academic and research institutes, pharmaceutical and biotechnology companies, cosmetics industry and other end users. By type market is segmented to liver, lung, kidney, heart and others. The report also focuses on regional segmentation of the market.
Further, it explains the major drivers and regional dynamics of the global market and current trends within the industry. It also includes information about the industry structure and competitive landscape as well as the impact of COVID-19 on the market. The report includes detailed profiles of the major players in the global organ-on-a-chip market.
BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.
The global market for organ-on-a-chip should grow from $11.3 million in 2018 to $60.6 million by 2023 at a compound annual growth rate (CAGR) of 39.9% from 2018 to 2023.
- 56 data tables and 49 additional tables
- An overview of global market for organ-on-a-chip within the industry
- Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023
- Description of potential applications in pharmaceutical and life science research sectors, including preclinical drugs testing, drug screening, personalized medicine, phenotypic screening, lead optimization and disease modelling
- Information on multi-channel 3-D microfluidic cell culture chip and discussion of their ability to imitate human micro environment in vitro
- Discussion on how organ on a chip is emerging as a priority testing alternative which is replacing animals in life science research, toxicology testing and drug development studies
- Knowledge about implementation of 3rs (replacement, refinement and reduction of animals-based research) in the industry
- Insights into government programs and policies in support of organ on chip and coverage of revised laws involving animal testing
- Company profiles of the top players in the industry, including Emulate Inc., Hurel Corp., InSphero, Organovo and SynVivo